Association Between Pretreatment Blood 25-Hydroxyvitamin D Level and Survival Outcomes in Patients With Clinically Localized Prostate Cancer: An Updated Meta-Analysis

References

• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi: 10.3322/caac.21763.
   PubMed Web of Science ®Google Scholar
• Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, Buckley DI, Griffin JC, Cookson MS. Updates to advanced prostate cancer: AUA/SUO guideline (2023). J Urol. 2023;209(6):1082–1090. doi: 10.1097/JU.0000000000003452.
   PubMed Web of Science ®Google Scholar
• Nieder C, Stanisavljevic L. Independent validation of a risk stratification model predicting survival in patients with metastatic hormone-sensitive prostate cancer. Anticancer Res. 2022;42(7):3675–3679. doi: 10.21873/anticanres.15856.
   PubMed Web of Science ®Google Scholar
• Song P, Wang J, Shu M, Di X, Li Y, Qing Y, Dong Q. Prognosis of men with high-risk prostate cancer stratified by risk factors: a population-based retrospective cohort study. Transl Cancer Res. 2020;9(10):6013–6025. doi: 10.21037/tcr-20-1578.
   PubMed Web of Science ®Google Scholar
• Farha MW, Salami SS. Biomarkers for prostate cancer detection and risk stratification. Ther Adv Urol. 2022;14:17562872221103988. doi: 10.1177/17562872221103988.
   Web of Science ®Google Scholar
• Adamaki M, Zoumpourlis V. Prostate cancer biomarkers: from diagnosis to prognosis and precision-guided therapeutics. Pharmacol Ther. 2021;228:107932. doi: 10.1016/j.pharmthera.2021.107932.
   PubMed Web of Science ®Google Scholar
• Heaney RP. Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr. 2004;80(6 Suppl):1706S–1709S. doi: 10.1093/ajcn/80.6.1706S.
   PubMed Web of Science ®Google Scholar
• Trump DL, Chadha MK, Sunga AY, Fakih MG, Ashraf U, Silliman CG, Hollis BW, Nesline MK, Tian L, Tan W, et al. Vitamin D deficiency and insufficiency among patients with prostate cancer. BJU Int. 2009;104(7):909–914. doi: 10.1111/j.1464-410X.2009.08531.x.
   PubMed Web of Science ®Google Scholar
• Murphy AB, Nyame Y, Martin IK, Catalona WJ, Hollowell CMP, Nadler RB, Kozlowski JM, Perry KT, Kajdacsy-Balla A, Kittles R, et al. Vitamin D deficiency predicts prostate biopsy outcomes. Clin Cancer Res. 2014;20(9):2289–2299. 10.1158/1078-0432.CCR-13-3085
   PubMed Web of Science ®Google Scholar
• Gilbert R, Metcalfe C, Fraser WD, Donovan J, Hamdy F, Neal DE, Lane JA, Martin RM. Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int J Cancer. 2012;131(5):1187–1196. doi: 10.1002/ijc.27327.
   PubMed Web of Science ®Google Scholar
• Trump DL, Aragon-Ching JB. Vitamin D in prostate cancer. Asian J Androl. 2018;20(3):244–252. doi: 10.4103/aja.aja_14_18.
   PubMed Web of Science ®Google Scholar
• Holt SK, Kolb S, Fu R, Horst R, Feng Z, Stanford JL. Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis. Cancer Epidemiol. 2013;37(5):666–670. doi: 10.1016/j.canep.2013.07.005.
   PubMed Web of Science ®Google Scholar
• Mondul AM, Weinstein SJ, Moy KA, Männistö S, Albanes D. Circulating 25-hydroxyvitamin D and prostate cancer survival. Cancer Epidemiol Biomarkers Prev. 2016;25(4):665–669. doi: 10.1158/1055-9965.EPI-15-0991.
   PubMed Web of Science ®Google Scholar
• Nair-Shalliker V, Bang A, Egger S, Clements M, Gardiner RA, Kricker A, Seibel MJ, Chambers SK, Kimlin MG, Armstrong BK, et al. Post-treatment levels of plasma 25- and 1,25-dihydroxy vitamin D and mortality in men with aggressive prostate cancer. Sci Rep. 2020;10(1):7736. doi: 10.1038/s41598-020-62182-w.
   PubMed Web of Science ®Google Scholar
• Stroomberg HV, Vojdeman FJ, Madsen CM, Helgstrand JT, Schwarz P, Heegaard A-M, Olsen A, Tjønneland A, Struer Lind B, Brasso K, et al. Vitamin D levels and the risk of prostate cancer and prostate cancer mortality. Acta Oncol. 2021;60(3):316–322. doi: 10.1080/0284186X.2020.1837391.
   PubMed Web of Science ®Google Scholar
• McGrowder D, Tulloch-Reid MK, Coard KCM, McCaw-Binns AM, Ferguson TS, Aiken W, Harrison L, Anderson SG, Jackson MD. Vitamin D deficiency at diagnosis increases all-cause and prostate cancer-specific mortality in Jamaican men. Cancer Control. 2022;29:10732748221131225. doi: 10.1177/10732748221131225.
   Web of Science ®Google Scholar
• Tretli S, Hernes E, Berg JP, Hestvik UE, Robsahm TE. Association between serum 25(OH)D and death from prostate cancer. Br J Cancer. 2009;100(3):450–454. doi: 10.1038/sj.bjc.6604865.
   PubMed Web of Science ®Google Scholar
• Fang F, Kasperzyk JL, Shui I, Hendrickson W, Hollis BW, Fall K, Ma J, Gaziano JM, Stampfer MJ, Mucci LA, et al. Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PLoS One. 2011;6(4):e18625. doi: 10.1371/journal.pone.0018625.
   PubMed Web of Science ®Google Scholar
• Gupta D, Trukova K, Popiel B, Lammersfeld C, Vashi PG. The association between pre-treatment serum 25-hydroxyvitamin D and survival in newly diagnosed stage IV prostate cancer. PLoS One. 2015;10(3):e0119690. doi: 10.1371/journal.pone.0119690.
   PubMed Web of Science ®Google Scholar
• Brändstedt J, Almquist M, Manjer J, Malm J. Vitamin D, PTH, and calcium in relation to survival following prostate cancer. Cancer Causes Control. 2016;27(5):669–677. doi: 10.1007/s10552-016-0740-7.
   PubMed Web of Science ®Google Scholar
• Song ZY, Yao Q, Zhuo Z, Ma Z, Chen G. Circulating vitamin D level and mortality in prostate cancer patients: a dose-response meta-analysis. Endocr Connect. 2018;7(12):R294–R303. doi: 10.1530/EC-18-0283.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269, W64. doi: 10.7326/0003-4819-151-4-200908180-00135.
   PubMed Web of Science ®Google Scholar
• Wells G, Shea B, O’Connell D, Peterson J, Welch V, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses; 2023 [accessed 2023 Dec 18]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp..
   Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–1101. 10.2307/2533446
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. 10.1136/bmj.315.7109.629
   PubMed Web of Science ®Google Scholar
• Meyer HE, Støer NC, Samuelsen SO, Blomhoff R, Robsahm TE, Brustad M, Giovannucci EL, Bjørge T. Long term association between serum 25-hydroxyvitamin D and mortality in a cohort of 4379 men. PLoS One. 2016;11(3):e0151441. doi: 10.1371/journal.pone.0151441.
   PubMed Web of Science ®Google Scholar
• Weinstein SJ, Mondul AM, Yu K, Layne TM, Abnet CC, Freedman ND, Stolzenberg-Solomon RZ, Lim U, Gail MH, Albanes D, et al. Circulating 25-hydroxyvitamin D up to 3 decades prior to diagnosis in relation to overall and organ-specific cancer survival. Eur J Epidemiol. 2018;33(11):1087–1099. doi: 10.1007/s10654-018-0428-2.
   PubMed Web of Science ®Google Scholar
• Weinstein SJ, Mondul AM, Layne TM, Yu K, Huang J, Stolzenberg-Solomon RZ, Ziegler RG, Purdue MP, Huang W-Y, Abnet CC, et al. Prediagnostic serum vitamin D, vitamin D binding protein isoforms, and cancer survival. JNCI Cancer Spectr. 2022;6(2):pkac019. doi: 10.1093/jncics/pkac019.
   PubMed Web of Science ®Google Scholar
• Sha S, Chen LJ, Brenner H, Schöttker B. Associations of 25-hydroxyvitamin D status and vitamin D supplementation use with mortality due to 18 frequent cancer types in the UK Biobank cohort. Eur J Cancer. 2023;191:113241. doi: 10.1016/j.ejca.2023.113241.
   PubMed Web of Science ®Google Scholar
• Michaëlsson K, Baron JA, Snellman G, Gedeborg R, Byberg L, Sundström J, Berglund L, Arnlöv J, Hellman P, Blomhoff R, et al. Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am J Clin Nutr. 2010;92(4):841–848. doi: 10.3945/ajcn.2010.29749.
   PubMed Web of Science ®Google Scholar
• Nyame YA, Murphy AB, Bowen DK, Jordan G, Batai K, Dixon M, Hollowell CMP, Kielb S, Meeks JJ, Gann PH, et al. Associations between serum vitamin D and adverse pathology in men undergoing radical prostatectomy. J Clin Oncol. 2016;34(12):1345–1349. doi: 10.1200/JCO.2015.65.1463.
   PubMed Web of Science ®Google Scholar
• Tewari AK, Stockert JA, Yadav SS, Yadav KK, Khan I. Inflammation and prostate cancer. Adv Exp Med Biol. 2018;1095:41–65. doi: 10.1007/978-3-319-95693-0_3.
   PubMed Web of Science ®Google Scholar
• Xie D-D, Chen Y-H, Xu S, Zhang C, Wang D-M, Wang H, Chen L, Zhang Z-H, Xia M-Z, Xu D-X, et al. Low vitamin D status is associated with inflammation in patients with prostate cancer. Oncotarget. 2017;8(13):22076–22085. doi: 10.18632/oncotarget.16195.
   PubMedGoogle Scholar
• Zhang Z-H, Liu M-D, Yao K, Xu S, Yu D-X, Xie D-D, Xu D-X. Vitamin D deficiency aggravates growth and metastasis of prostate cancer through promoting EMT in two β-catenin-related mechanisms. J Nutr Biochem. 2023;111:109177. doi: 10.1016/j.jnutbio.2022.109177.
   PubMed Web of Science ®Google Scholar
• Shahvazi S, Soltani S, Ahmadi SM, de Souza RJ, Salehi-Abargouei A. The effect of vitamin D supplementation on prostate cancer: a systematic review and meta-analysis of clinical trials. Horm Metab Res. 2019;51(1):11–21. doi: 10.1055/a-0774-8809.
   PubMed Web of Science ®Google Scholar